- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances and Perspectives in Cancer Drug Design
Authors
Keywords
-
Journal
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
Volume 90, Issue 1 suppl 2, Pages 1233-1250
Publisher
FapUNIFESP (SciELO)
Online
2018-05-13
DOI
10.1590/0001-3765201820170823
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Innovation in the pharmaceutical industry: New estimates of R&D costs
- (2016) Joseph A. DiMasi et al. JOURNAL OF HEALTH ECONOMICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Putting a price on cancer
- (2016) Richard Sullivan et al. Nature Reviews Clinical Oncology
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
- (2016) Duncan E. Scott et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity
- (2016) Luma G. Magalhaes et al. PLoS One
- Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
- (2015) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Drug Discovery and Repurposing at Memorial Sloan Kettering Cancer Center: Chemical Biology Drives Translational Medicine
- (2014) Bhavneet Bhinder et al. ACS Chemical Biology
- An analysis of FDA-approved drugs for oncology
- (2014) Michael S. Kinch DRUG DISCOVERY TODAY
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Phenotypic screening in cancer drug discovery — past, present and future
- (2014) John G. Moffat et al. NATURE REVIEWS DRUG DISCOVERY
- Oncology Drug Discovery: Planning a Turnaround
- (2014) C. Toniatti et al. Cancer Discovery
- A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
- (2013) K. Masui et al. CARCINOGENESIS
- Targeted cancer therapy – Are the days of systemic chemotherapy numbered?
- (2013) Won Duk Joo et al. MATURITAS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
- (2012) C. M. Chapman et al. CLINICAL CANCER RESEARCH
- Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
- (2012) Elisabet Wahlberg et al. NATURE BIOTECHNOLOGY
- A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions
- (2011) Nathan Fishkin et al. CHEMICAL COMMUNICATIONS
- Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity
- (2011) M. V. Ramana Reddy et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
- (2010) Stefania Redana et al. BMC CANCER
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Targeted cancer therapies
- (2010) Saurabh Aggarwal NATURE REVIEWS DRUG DISCOVERY
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
- (2009) Peter B. Bach NEW ENGLAND JOURNAL OF MEDICINE
- Estrogen-Related Receptor α Is Critical for the Growth of Estrogen Receptor–Negative Breast Cancer
- (2008) Rebecca A. Stein et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- Mouse xenograft models vs GEM models for human cancer therapeutics
- (2008) A. Richmond et al. Disease Models & Mechanisms
- Chemistry strategies in early drug discovery: an overview of recent trends
- (2008) Matteo Colombo et al. DRUG DISCOVERY TODAY
- Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress
- (2008) Robert K. Oldham et al. JOURNAL OF CLINICAL ONCOLOGY
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started